TABLE 1

Percent Seropositivity to HPV Types 6, 11, 16, and 18 in Male and Female Subjects After 10 Years by Using the cLIA and the IgG LIA Assays in the EVG Per-Prootco Population

HPV cLIA AssayHPV IgG LIA Assay
GirlsBoysGirlsBoys
% Seropositivity (95% CI)% Seropositivity (95% CI)% Seropositivity (95% CI)% Seropositivity (95% CI)
HPV Type
 Anti–HPV-691.0 (86.4–94.4)86.6 (80.9–91.2)94.5 (90.7–97.0)91.3 (86.4–94.8)
 Anti–HPV-1190.1 (85.4–93.7)87.2 (81.5–91.6)91.1 (86.7–94.4)89.7 (84.6–93.6)
 Anti–HPV-1697.7 (94.7–99.3)94.1 (89.6–97.0)98.7 (96.3–99.7)97.4 (94.1–99.2)
 Anti–HPV-1861.4 (54.6–67.8)59.6 (52.2–66.7)78.5 (72.2–83.6)77.0 (70.5–82.7)
  • The indicated time point of 10 years is relative to the day of injection of dose 1 of the 4vHPV vaccine.